ArticleNature and science of sleep2020
Feasibility of Patient-Controlled Sleep with Dexmedetomidine in Treating Chronic Intractable Insomnia.
Article in Nature and science of sleep, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- A multimodal sleep intervention improves sleep quality and architecture in chronic insomnia: a prospective exploratory study.Frontiers in medicine · 2026Trial
- Role of Preoptic Area γ-Aminobutyric Acid-mediated Neurons in Distinctly Regulating Sleep and Rousability during Dexmedetomidine Sedation in Mice.Anesthesiology · 2026Article
- Bionic sleep therapy for refractory insomnia: a case report and literature review.BMC anesthesiology · 2026Review
- Anesthesia-Informed Approaches to Insomnia: Shared Neural Circuits, Biomimetic Sleep, and Emerging Interventional Strategies.Nature and science of sleep · 2026Review
- Therapeutic Potential of Anesthesiology for Sleep Disorders in the Perioperative Period.Current neuropharmacology · 2026Review
- Multimodal neuroimaging of locus coeruleus-default mode network connectivity for predicting dexmedetomidine response in chronic insomnia disorder.Frontiers in psychiatry · 2026Article
- Feasibility of rTMS combined with dexmedetomidine in chronic insomnia disorder.Scientific reports · 2025Article
- Dexmedetomidine ameliorates cognitive and affective deficits by modulating neuroinflammation and neurogenesis in an Alzheimer's disease mouse model.Frontiers in aging neuroscience · 2025Article
- Sleep disorders in cancer: interactions and intrinsic links.Frontiers in oncology · 2025Review
- Effective Dexmedetomidine Dose for Stage N2 Sleep Induction and Associated Factors in Depression-Related Insomnia: A Polysomnography-Based Analysis.Nature and science of sleep · 2025Article
- The 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder: a biased coin design up-and-down sequential allocation trial.BMC anesthesiology · 2024Article
- Daytime dexmedetomidine sedation with closed-loop acoustic stimulation alters slow wave sleep homeostasis in healthy adults.BJA open · 2024Article
- High-density lipoproteins and non-alcoholic fatty liver disease.Atherosclerosis plus · 2023Article
- Dexmedetomidine prevents spatial learning and memory impairment induced by chronic REM sleep deprivation in rats.Sleep and biological rhythms · 2023Article
- Effect of butylphthalide injection combined with gastrodin to improve sTRAIL and inflammatory factors in elderly patients with cerebral infarction.American journal of translational research · 2023Article
- Dexmedetomidine in the Treatment of Depression: An Up-to-date Narrative Review.Clinical practice and epidemiology in mental health : CP & EMH · 2023Review
- NMDA Receptors in the Lateral Preoptic Hypothalamus Are Essential for Sustaining NREM and REM Sleep.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Multimodal sleep, an innovation for treating chronic insomnia: case report and literature review.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021Review
- Recent Advances in the Clinical Value and Potential of Dexmedetomidine.Journal of inflammation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient-controlled analgesia (PCA) is an "on-demand" system which allows patients to self-administer intravenous medications in small bolus doses. Based on the principles of PCA, we developed Patient-Controlled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were replaced with dexmedetomidine (Dex), an alpha-2 agonist widely used for premedication, sedation, anxiolysis and analgesia. The purpose of this study was to assess the feasibility of the new method for the treatment of chronic intractable insomnia. PATIENTS AND
methodsPatients with chronic intractable insomnia undergoing PCSL (n=20) were evaluated with the Pittsburgh Sleep Quality Index (PSQI), Symptom Checklist 90 (SCL-90), Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) before and after the treatment. The patient characteristics, overall outcomes and related side effects were also assessed.
resultsFifteen patients completed the treatment protocol. The duration of PCSL varied from a few days to four months, and the dosage of Dex gradually decreased without eliciting signs or symptoms of tolerance or physical dependence. The sleep quality improvement occurred immediately after the therapy in 12/15 patients, and of which, 7/12 patients achieved continuously improved sleep quality in follow-up.
conclusionPCSL with Dex might be a potential treatment for patients with chronic intractable insomnia. However, it is an off-label use, and the potential side effects of dexmedetomidine with long-term use needs further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.